Randi B. Gombos, Ph.D.
Affiliations: | 2012 | Physiology | University of Alberta, Edmonton, Alberta, Canada |
Area:
Physiology BiologyGoogle:
"Randi Gombos"Parents
Sign in to add mentor| Denise G. Hemmings | grad student | 2012 | University of Alberta | |
| (Cytomegalovirus and vascular function during pregnancy.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kerage D, Gombos RB, Wang S, et al. (2021) Sphingosine 1-phosphate-induced nitric oxide production simultaneously controls endothelial barrier function and vascular tone in resistance arteries. Vascular Pharmacology. 106874 |
| Waight J, Manrique M, Gombos R, et al. (2019) Preclinical functional characterization of AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody for the treatment of patients with early and advanced malignancies. Journal of Clinical Oncology. 37: e14126-e14126 |
| Chand D, Waight JD, Paltrinieri E, et al. (2019) Abstract 2390: FcgR co-engagement by anti-TIGIT monoclonal antibodies enhances T cell functionality and antitumor immune responses Cancer Research. 79: 2390-2390 |
| Waight JD, Chand D, Dietrich S, et al. (2018) Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens. Cancer Cell. 33: 1033-1047.e5 |
| Gombos RB, Gonzalez A, Manrique M, et al. (2018) Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. Plos One. 13: e0191926 |
| Waight JD, Chand D, Dietrich S, et al. (2018) Abstract 2721: Selective FcγR engagement by CTLA-4 antibodies results in increased functional activity Cancer Research. 78: 2721-2721 |
| Drouin EE, Gonzalez A, Tang H, et al. (2016) Abstract 5005: AGEN1884 and AGEN2041: Two functionally distinct anti-CTLA-4 antagonist antibodies Cancer Research. 76: 5005-5005 |
| Gonzalez AM, Breous E, Manrique ML, et al. (2016) Abstract 3220: A novel agonist antibody (INCAGN01876) that targets the costimulatory receptor GITR Cancer Research. 76: 3220-3220 |
| Gonzalez AM, Manrique ML, Breous E, et al. (2016) Abstract 3204: INCAGN01949: an anti-OX40 agonist antibody with the potential to enhance tumor-specific T-cell responsiveness, while selectively depleting intratumoral regulatory T cells Cancer Research. 76: 3204-3204 |
| Gombos RB, Kolodkin-Gal D, Eslamizar L, et al. (2015) Inhibitory effect of individual or combinations of broadly neutralizing antibodies and antiviral reagents against cell-free and cell-to-cell HIV-1 transmission. Journal of Virology |